Status regarding Novo Nordisk's holding of own shares


In continuation of the company's announcement dated 7 August 2009
concerning Novo Nordisk's share repurchase programme, and pursuant to
Section 29 of the Danish Securities Trading Act, this is to report
that as of today, Novo Nordisk A/S (NYSE:NVO) and its wholly-owned
affiliates own more than 5% of the total share capital in Novo
Nordisk A/S.

As per 1 December 2009, Novo Nordisk A/S and its wholly-owned
affiliates own 31,063,977 of its own B shares of DKK 1, corresponding
to a total nominal value of DKK 31,063,977 or 5.0% of the total share
capital.

Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 29,000
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:

Media:                 Investors:

Mette Kruse Danielsen  Mads Veggerby Lausten
Tel: (+45) 4442 3883   Tel: (+45) 4443 7919
mkd@novonordisk.com    mlau@novonordisk.com

                       Kasper Roseeuw Poulsen
                       Tel: (+45) 4442 4471
                       krop@novonordisk.com

In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   hrmm@novonordisk.com


Company Announcement no 71 / 2009




http://hugin.info/2013/R/1358531/330817.pdf


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.